Ginkgo revenue misses as it pivots to autonomous labs

 

Ginkgo Bioworks Q4 2025 non-GAAP EPS -$1.41 beats estimates while $33.0M revenue misses as it pivots to autonomous labs

• Non-GAAP EPS of -$1.41 improved 30% YoY, while revenue of $33.0M declined 25% YoY.
• Core cell engineering revenue fell 26% YoY in Q4 to $26M.
• Full-year cell engineering revenue was $133M, down from $174M in 2024.
• Biosecurity revenue reached $37M in 2025; business will be divested, Ginkgo retaining a minority stake.
• Company will no longer provide revenue guidance, emphasizing cash burn and autonomous lab execution instead.
• Cash burn cut 55%, with 2026 cash burn guided to $125–150M, improving from 2025's $171M actual.
• Total adjusted EBITDA loss improved to -$167M from -$293M on restructuring-driven opex cuts.
• Year-end cash balance was about $430M, giving meaningful runway despite ongoing losses.
• Signed $47M Department of Energy contract to build 97-rack autonomous lab at PNNL.

https://finviz.com/quote.ashx?t=DNA&p=d